BRPI9909471B8 - processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra - Google Patents

processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra

Info

Publication number
BRPI9909471B8
BRPI9909471B8 BRPI9909471A BRPI9909471A BRPI9909471B8 BR PI9909471 B8 BRPI9909471 B8 BR PI9909471B8 BR PI9909471 A BRPI9909471 A BR PI9909471A BR PI9909471 A BRPI9909471 A BR PI9909471A BR PI9909471 B8 BRPI9909471 B8 BR PI9909471B8
Authority
BR
Brazil
Prior art keywords
ribofuranosyl
isopropylamino
benzimidazole
dichloro
beta
Prior art date
Application number
BRPI9909471A
Other languages
English (en)
Inventor
Hodgson Anne
Howard Carter Barry
Huang Lian-Feng
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI9909471B1 publication Critical patent/BRPI9909471B1/pt
Publication of BRPI9909471B8 publication Critical patent/BRPI9909471B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"formas vi e cristalina de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol, e, processos para o tratamento ou profilaxia de uma infecção viral em ser humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol" a invenção refere-se a forma vi de 5,6-dicloro-2-(isopropilamino)-1-(<225>-l-ribofuranosil)-1h-benzimidazol, a composições farmacêuticas e a seu uso em terapia medicinal.
BRPI9909471A 1998-04-07 1999-04-01 processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra BRPI9909471B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807355.4A GB9807355D0 (en) 1998-04-07 1998-04-07 Antiviral compound
PCT/EP1999/002213 WO1999051617A2 (en) 1998-04-07 1999-04-01 FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE

Publications (2)

Publication Number Publication Date
BRPI9909471B1 BRPI9909471B1 (pt) 2018-11-21
BRPI9909471B8 true BRPI9909471B8 (pt) 2021-05-25

Family

ID=10829933

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9909471A BRPI9909471B8 (pt) 1998-04-07 1999-04-01 processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra
BR9909471-1A BR9909471A (pt) 1998-04-07 1999-04-01 Formas vi e cristalina de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento ou profilaxia de uma infecção viral em ser humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9909471-1A BR9909471A (pt) 1998-04-07 1999-04-01 Formas vi e cristalina de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento ou profilaxia de uma infecção viral em ser humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol

Country Status (40)

Country Link
US (1) US6482939B1 (pt)
EP (1) EP1070078B1 (pt)
JP (1) JP2002510702A (pt)
KR (1) KR100573635B1 (pt)
CN (1) CN1222534C (pt)
AP (1) AP2000001946A0 (pt)
AR (1) AR014973A1 (pt)
AT (1) ATE231517T1 (pt)
AU (1) AU753527B2 (pt)
BG (1) BG104909A (pt)
BR (2) BRPI9909471B8 (pt)
CA (1) CA2327495C (pt)
CO (1) CO5011057A1 (pt)
DE (1) DE69905025T2 (pt)
DK (1) DK1070078T3 (pt)
EA (1) EA002953B1 (pt)
EE (1) EE04121B1 (pt)
EG (1) EG24597A (pt)
ES (1) ES2191429T3 (pt)
GB (1) GB9807355D0 (pt)
GE (1) GEP20022840B (pt)
HK (1) HK1032060A1 (pt)
HR (1) HRP20000670B1 (pt)
HU (1) HUP0101549A3 (pt)
ID (1) ID26573A (pt)
IL (2) IL138559A0 (pt)
IS (1) IS5634A (pt)
MA (1) MA26617A1 (pt)
NO (1) NO316896B1 (pt)
NZ (1) NZ507012A (pt)
OA (1) OA11534A (pt)
PE (1) PE20000356A1 (pt)
PL (1) PL194752B1 (pt)
PT (1) PT1070078E (pt)
SI (1) SI1070078T1 (pt)
SK (1) SK283735B6 (pt)
TR (1) TR200002847T2 (pt)
WO (1) WO1999051617A2 (pt)
YU (1) YU58600A (pt)
ZA (1) ZA200005197B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
US20110008463A1 (en) * 2008-03-12 2011-01-13 Jan Pieter Hendrik Bosselaers Combinations of hydroxypyrion compounds and silver compounds
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
WO2023105483A1 (en) * 2021-12-10 2023-06-15 Assembly Biosciences, Inc. Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
WO2024081308A1 (en) 2022-10-12 2024-04-18 Takeda Pharmaceutical Company Limited Method of preparing maribavir

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399987A (en) 1965-08-02 1968-09-03 United States Borax Chem 2-alkylaminobenzimidazoles as herbicides
CH443777A (de) 1965-08-06 1968-02-15 Agripat Sa Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
AU5447094A (en) 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
GB9600143D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
GB2319961A (en) * 1996-12-07 1998-06-10 Glaxo Group Ltd Pharmaceutical composition for treatment of restenosis
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
EP1070078A2 (en) 2001-01-24
EG24597A (en) 2009-12-14
AU3703899A (en) 1999-10-25
GEP20022840B (en) 2002-11-25
IL138559A (en) 2006-12-31
HUP0101549A2 (hu) 2001-10-28
NO20005003D0 (no) 2000-10-04
OA11534A (en) 2004-05-06
ID26573A (id) 2001-01-18
SK14822000A3 (sk) 2001-07-10
AU753527B2 (en) 2002-10-17
ATE231517T1 (de) 2003-02-15
WO1999051617A3 (en) 1999-12-09
NZ507012A (en) 2003-06-30
KR20010074473A (ko) 2001-08-04
AR014973A1 (es) 2001-04-11
CO5011057A1 (es) 2001-02-28
BR9909471A (pt) 2000-12-19
MA26617A1 (fr) 2004-12-20
EA200000909A1 (ru) 2001-06-25
PL343712A1 (en) 2001-08-27
JP2002510702A (ja) 2002-04-09
AP2000001946A0 (en) 2000-12-31
SI1070078T1 (en) 2003-08-31
US6482939B1 (en) 2002-11-19
HUP0101549A3 (en) 2003-07-28
PE20000356A1 (es) 2000-04-26
PL194752B1 (pl) 2007-07-31
DE69905025D1 (de) 2003-02-27
ES2191429T3 (es) 2003-09-01
HK1032060A1 (en) 2001-07-06
KR100573635B1 (ko) 2006-04-26
CN1222534C (zh) 2005-10-12
BG104909A (bg) 2001-06-29
NO316896B1 (no) 2004-06-14
IS5634A (is) 2000-09-22
YU58600A (sh) 2003-04-30
TR200002847T2 (tr) 2001-01-22
SK283735B6 (sk) 2003-12-02
EE200000585A (et) 2002-04-15
NO20005003L (no) 2000-12-06
IL138559A0 (en) 2001-10-31
CA2327495A1 (en) 1999-10-14
CA2327495C (en) 2009-01-20
CN1304413A (zh) 2001-07-18
DK1070078T3 (da) 2003-05-19
GB9807355D0 (en) 1998-06-03
HRP20000670A2 (en) 2000-12-31
EE04121B1 (et) 2003-08-15
ZA200005197B (en) 2001-09-27
PT1070078E (pt) 2003-06-30
HRP20000670B1 (en) 2004-04-30
WO1999051617A2 (en) 1999-10-14
EP1070078B1 (en) 2003-01-22
EA002953B1 (ru) 2002-12-26
BRPI9909471B1 (pt) 2018-11-21
DE69905025T2 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR0114321A (pt) Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
ATE385797T1 (de) Phosphonatverbindungen
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
BRPI0508876A (pt) pró medicamentos de agentes antivirais de piperazina e piperidina substituìda
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR9714059A (pt) S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
BR0316407A (pt) Derivados de nucleosìdeo antiviral
BG101118A (en) Therapeutical compounds
BR9810745A (pt) Derivados de benzimidazol
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
BRPI9909471B8 (pt) processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0215016A (pt) Piridoquinoxalinas antivirìcas
BR9908522A (pt) Composto, pró-droga, intermediário para a preparação de um composto, composição farmacêutica, processos para tratar e prevenir infecção por pneumovìrus, para tratar células em cultura, para tratar materiais biológicos, e, para preparar um composto
SE0004101D0 (sv) New use
NO983090L (no) Terapeutiske forbindelser